# APL-102 Capsule in Patients With Advanced Solid Tumors

> **NCT05055518** · PHASE1 · SUSPENDED · sponsor: **Apollomics Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** APL-102 Capsules

## Key facts

- **NCT ID:** NCT05055518
- **Lead sponsor:** Apollomics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-08-02
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Voluntarily suspended (due to adjustments in corporate development strategy, not for reasons related to safety or efficacy.)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055518, "APL-102 Capsule in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05055518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*